156100 On Other Exchanges
Symbol
Exchange
KOSDAQ

l&k biomed co ltd (156100) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for L&K BIOMED CO LTD (156100)
\

Related News

No related news articles were found.

l&k biomed co ltd (156100) Related Businessweek News

No Related Businessweek News Found

l&k biomed co ltd (156100) Details

L&K Biomed Ltd. engages in the research and development, manufacture, and sale of medical devices in South Korea and internationally. The company offers cervical spine products, such as anterior cervical plate systems, posterior cervical fixation systems, and anterior cervical cage systems; and thoraco-lumbar spine products, including spinal fixation systems, MIS spinal systems, PLIF/TPLIF cages, TLIF cages, ALIF cages, and DLIF cages. It also develops cardiovascular products and cell simulation kits. The company was founded in 2008 and is headquartered in Seoul, South Korea.

Founded in 2008

l&k biomed co ltd (156100) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

l&k biomed co ltd
L&K Biomed Ltd., Annual General Meeting, Mar 29, 2019

L&K Biomed Ltd., Annual General Meeting, Mar 29, 2019, at 09:01 Korea Standard Time.

IMPLANET and L&K BIOMED Co. Ltd. Finalizes Their Partnership with Cross-Distribution Agreements Covering Asia and Europe

IMPLANET announced that it has finalized the partnership with L&K BIOMED Co. Ltd. In January, IMPLANET entered into a distribution agreement with Aegis Spine, L&K BIOMED’s US subsidiary, under which it can harness the expertise of Aegis Spine’s team for the commercialization of its products in the United States, a priority market for the Company. In line with the previous announcement, the strategic alliance between IMPLANET and L&K BIOMED has now been finalized, with cross-distribution agreements covering their respective products in Asia and Europe. In the United States: IMPLANET America will pool its resources with those of Aegis Spine to accelerate the commercialization of its JAZZ® platform. The development of existing and complementary solutions incorporating both companies’ technologies will be a key lever for this. In Asia and Oceania: L&K BIOMED will distribute the JAZZ® platform alongside its product range. Initially, in addition to the South Korean market, the aim is to expand jointly into the Japanese market, the world’s second-largest market for medical technologies. Subsequently, they will target the Chinese market. In Europe: IMPLANET will distribute L&K BIOMED’s products, which complement the JAZZ® platform, in France, the United Kingdom and Germany, with a view to establishing itself as a major player in these markets.

L&K Biomed Ltd., Annual General Meeting, Mar 29, 2018

L&K Biomed Ltd., Annual General Meeting, Mar 29, 2018, at 09:00 Korea Standard Time.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

156100 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 156100.
View Industry Companies
 

Industry Analysis

156100

Industry Average

Valuation 156100 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact L&K BIOMED CO LTD, please visit www.lnkbiomed.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.